Cancer Antibodies Inc
Cancer Antibodies Inc is a non-profit organization dedicated to revolutionizing cancer treatment by developing novel methods to identify unique antigenic sites on cancer cells. Their mission is to treat and cure cancer with minimal or no side effects, using a platform that finds new cancer-specific targets (neoantigens) on the surface of cancer cells. They seek partners and collaborators to advance this research into clinical applications. The organization has presented research at major conferences such as AACR 2024 and ASCO 2022, showcasing discoveries like the surface antigen SLC39A7 (ZIP7) and the development of antibodies that can kill cancer cells without harming normal cells. They focus on creating targeted therapies that address the challenges of current treatments, such as toxicity and mutation-driven resistance.
Industries
Nr. of Employees
small (1-50)
Products
ASCO 2022 abstract and poster: Novel platform for identifying multiple cancer-specific antigens
Abstract published and poster presented at the American Society of Clinical Oncology (ASCO) 2022 describing a platform for discovery of cancer-specific surface antigens and antibody results.
AACR 2024 poster: Discovery of SLC39A7 (ZIP7) as a breast cancer surface antigen
Conference poster presented at the American Association for Cancer Research (AACR) 2024 reporting identification of SLC39A7 (ZIP7) as a cell-surface antigen in breast cancer.
ASCO 2022 video and recorded poster presentation
Recorded presentation materials (video) used to explain the discovery platform and experimental results presented at ASCO 2022.
ASCO 2022 abstract and poster: Novel platform for identifying multiple cancer-specific antigens
Abstract published and poster presented at the American Society of Clinical Oncology (ASCO) 2022 describing a platform for discovery of cancer-specific surface antigens and antibody results.
AACR 2024 poster: Discovery of SLC39A7 (ZIP7) as a breast cancer surface antigen
Conference poster presented at the American Association for Cancer Research (AACR) 2024 reporting identification of SLC39A7 (ZIP7) as a cell-surface antigen in breast cancer.
ASCO 2022 video and recorded poster presentation
Recorded presentation materials (video) used to explain the discovery platform and experimental results presented at ASCO 2022.
Services
Collaborative research to apply a discovery platform that identifies novel cancer-specific surface antigens and generates antibodies for preclinical characterization.
Production of antibodies against discovered antigens and experimental validation of antibody specificity and cancer-cell killing in laboratory assays.
Collaborative research to apply a discovery platform that identifies novel cancer-specific surface antigens and generates antibodies for preclinical characterization.
Production of antibodies against discovered antigens and experimental validation of antibody specificity and cancer-cell killing in laboratory assays.
Expertise Areas
- Surface antigen discovery
- Therapeutic antibody discovery (xenoantibody approaches)
- Target validation and specificity testing
- Cell-based cytotoxicity assessment
Key Technologies
- Cell-surface antigen mapping
- Xenoantibody generation
- In vitro cell-based cytotoxicity assays
- Cross-donor target validation
News & Updates
The novel breast cancer surface antigen SLC39A7 (ZIP7) was discovered by CAI and presented at the AACR Annual Meeting on April 9, 2024.
Research on a novel platform for identifying multiple cancer-specific antigens was accepted for publication and presented at the ASCO Annual Meeting in June 2022, attended by over 40,000 participants.
Dr. Elliot Davis announced a new method to detect unique antigenic targets on cancer cells, which can be used for targeted therapy without harming normal cells. The research was presented at ASCO 2022.
Cancer Antibodies Inc. announced that their research abstract on a novel platform for identifying cancer-specific antigens was accepted for publication and presentation at the ASCO Annual Meeting in June 2022.
Dr. Elliot Davis and his team developed a method to detect unique antigenic targets on cancer cells, which can be used for highly targeted therapies with fewer side effects.
The novel breast cancer surface antigen SLC39A7 (ZIP7) was discovered by CAI and presented at the AACR Annual Meeting on April 9, 2024.
Research on a novel platform for identifying multiple cancer-specific antigens was accepted for publication and presented at the ASCO Annual Meeting in June 2022, attended by over 40,000 participants.
Dr. Elliot Davis announced a new method to detect unique antigenic targets on cancer cells, which can be used for targeted therapy without harming normal cells. The research was presented at ASCO 2022.
Cancer Antibodies Inc. announced that their research abstract on a novel platform for identifying cancer-specific antigens was accepted for publication and presentation at the ASCO Annual Meeting in June 2022.
Dr. Elliot Davis and his team developed a method to detect unique antigenic targets on cancer cells, which can be used for highly targeted therapies with fewer side effects.